New Discovery: Alpha Cells in the Pancreas May Play a Role in Type 1 Diabetes Development

Researchers studying pancreatic tissue from people with Type 1 diabetes and from laboratory mice prone to the disease noticed something unexpected: genes associated with antigen presentation were increasingly active in alpha cells as diabetes developed. Antigen presentation is a process where cells display pieces of molecules on their surface to alert the immune system. Previously, scientists thought only specialized immune cells performed this role in Type 1 diabetes.

Using imaging techniques, the team confirmed that alpha cells in both animal models and human patients showed higher levels of MHC class II molecules—the structures cells use to present antigens—as the autoimmune attack progressed.

The researchers identified the mechanism behind this transformation. When inflammatory cytokines—chemical signals released during inflammation—flood the pancreas, they activate a pathway inside alpha cells called JAK-STAT. This pathway then triggers the production of MHC class II molecules on the alpha cell surface.

This is a key mechanistic finding because it shows how the inflammatory environment in the pancreas during Type 1 diabetes development can reprogram normally non-immune cells to take on immune functions.

Once alpha cells acquire MHC class II, the study showed they gain additional immune capabilities. These activated alpha cells can take in, break down, and present antigens to immune cells. They also begin producing costimulatory molecules—signals that further activate T cells, the immune cells that attack beta cells in Type 1 diabetes.

In laboratory experiments, activated alpha cells successfully prompted CD4+ T cells (a type of immune cell involved in autoimmunity) to become more active and proliferate.

This discovery expands the understanding of Type 1 diabetes as an autoimmune disease. Rather than only professional antigen-presenting immune cells driving the attack on beta cells, endocrine cells within the pancreas itself—specifically alpha cells—may contribute by becoming de facto antigen presenters during disease progression.

The findings open new questions about the role of different pancreatic cells in sustaining the autoimmune attack and may eventually inform new strategies to understand or intervene in Type 1 diabetes development. However, this is fundamental research in early stages, and much more work is needed to translate these findings into clinical applications.

Source: Science advances. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.